9
2
2
day one, doxorubicin 50mg/M day one and oral Predni-
our initial list of differential diagnoses. Pulmonary in-
volvement in histiocytosis occurs in 20-40percent of
patients who may manifest with symptoms such as
solone 15mg 12hrly x 5/7. The course interval was 21
days and a total of five courses were envisaged but drug
administration was erratic and patient compliance poor
due to financial constraints.
8
cough, tachypnoea and dyspnoea and a male predomi-
nance is observed as was seen in our patient. He pre-
sented with a triad of fever, cough and dyspnoea to-
gether with generalized lymphadenopathy and in par-
ticular, prominent cervical lymphadenopathy.
The patient did not show any remarkable clinical im-
provement and eventually succumbed to the disease six
months after presentation.
The chest x-ray did not help in distinguishing this dis-
ease condition from tuberculosis as nodular infiltration,
pleural effusion and pneumothorax are also known to
8
occur in histiocytosis. We had to rely on histology of
the biopsied lymph nodes and the bone marrow biopsy.
A major drawback in the management of this patient
was our inability to arrive at a definitive conclusion of
the type of histiocytosis which requires the use of elec-
Discussion
Histiocytoses as a group of disorders are very rare with
an incidence of 4-5.4/million population. Males are
3
9
tron microscopy and immunohistochemistry to do so.
more commonly affected than females with a male to
female ratio of 1.5:1. Our patient was male. The disease
Chemotherapyis used for multisystemic disease with
local or constitutional symptoms as was seen in this pa-
tient. The paucity in our diagnostic facilities coupled
with the patient’s financial incapacitation was responsi-
ble for the delay in onset of appropriate therapy and all
these contributed to the untimely demise of this young
patient.
3
is seen in all age groups with peak incidence in child-
3
hood seen between ages 1-3years. However, other stud-
ies have shown age3 at diagnosis to range between nine
months to 15years with our patient falling into this age
bracket. Much effort has gone in2to the elucidation and
classification of these disorders though their patho-
physiology remains an enigma. Factors which have been
implicated in the aetiology and pathophysiology of these
5
disorders include viral infections , cellular and immune
Conclusion
6
,
7
dysfunction genetic factors and neoplastic mechanisms
amongst others.
We present a case of a 7 year old boy with malignant
histiocytosis, which was eventually fatal despite chemo-
therapeutic intervention. Although histiocytosis is very
rare, it is of paramount importance that clinicians sus-
pect this disease as well as other neoplasms in all cases
of generalized lymphadenopathy and investigate these
patients appropriately.
4
Because of the multisystemic involvement that charac-
terizes them, they can clinically mimic several other
more common diseases with tuberculosis being a major
differential diagnosis in our environment. Perhaps due to
the rarity of this condition, histiocytosis was not among
References
4
5
6
.
.
.
Abla O, Egeler RM, Weitzman
S. Langerhans cell histiocytosis:
Current concepts and treat-
7. Ornvold K, Carstensen H, Larsen
JK. Flow cytometric DNA analysis
of lesions from 18 children with
langerhans cell histiocytosis
(Histiocytosis X). Am J
Pathol. 1990; 136:1301-7.
8. Donnelly LF, Frush DP.
Langerhans' cell histiocytosis
showing low-attenuation mediasti-
nal mass and cystic lung dis-
ease. Am J Roentgenol. 2000;
174:877-8.
1
.
Chu T, D'Angio GJ, Favara BE,
Ladisch S, Nesbit M, Pritchard
J. Histiocytosis syndromes in chil-
dren. Lancet. 1987;2:41-2
Harris NL, Jaffe ES, Diebold J, et
al. World Health Organization
classification of neoplastic dis-
eases of the hematopoietic and
lymphoid tissues: report of the
Clinical Advisory Committee
meeting-Airlie House, Virginia,
November 1997. J Clin On-
col 1999; 17:3835-49.
ment. Cancer Treat Rev. 2010;
3
6:354-9.
2
.
Leahy MA, Krejci SM, Friednash
M, et al. Human herpesvirus 6 is
present in lesions of Langerhans
cell histiocytosis. J Invest Derma-
tol. Nov 1993; 101:642-5.
Hage C, Willman CL, Favara BE,
Isaacson PG. Langerhans' cell
histiocytosis (Histiocytosis X):
immunophenotype and growth
fraction. Hum Pathol. 1993;
9. Mierau GW, Favara BE, Brenman
JM. Electron microscopy in histio-
cytosis X. Ultrastruct
3
.
Carstensen H, Ornvold K. The
epidemiology of Langerhans cell
histiocytosis in children in Den-
mark 1975-89. Med Pediatr On-
col. 1993; 21:387-8.
2
4:840-5.
Pathol. 1982; 3:137-42.